Medpace
S&P 400
$587.52
+0.75%
Delayed · cached 15 min
Fair value analysis
MEDP
Medpace
$587.52
Close used for this calculation
$367.87Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
55/100
Quality radar
Consensus fair value
$367.87
Above FV▼ -37.4% against the close used
Model range $286.51 – $458.42
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$286.51Fair value$367.87Bull$458.42
FairClose
52-week traded range
52W low $393.4252W high $620.75
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Medpace closed at $587.52, 59.7% above the consensus fair value of $367.87 drawn from 6 valuation models.
Financial DNA score 55/100 — Good. P/E of 38.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$458.42
-22.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$305.60
-48.0%
EPS × 20x (sector P/E)
EPS=15.28, Sector P/E=20x
Peter Lynch (PEG)
$458.40
-22.0%
EPS × Growth% (PEG = 1 is fair)
EPS=15.28, g=30%
EV/EBITDA
$342.71
-41.7%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=562.11M
Reverse DCF
$587.52
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 16% | Historical: 40%
Margin of Safety
$286.51
-51.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=382.01, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.